IGF2BP2 Polymorphisms Are Associated with Clinical Characteristics and Development of Oral Cancer.
Gene Expression Regulation, Neoplastic
Gene Frequency
/ genetics
Genetic Association Studies
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Mouth Neoplasms
/ genetics
Odds Ratio
Polymorphism, Single Nucleotide
/ genetics
RNA, Messenger
/ genetics
RNA-Binding Proteins
/ genetics
Squamous Cell Carcinoma of Head and Neck
/ genetics
Survival Analysis
IGF2BP2
lymph node metastasis
oral cancer
polymorphism
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Aug 2020
07 Aug 2020
Historique:
received:
17
07
2020
revised:
05
08
2020
accepted:
06
08
2020
entrez:
14
8
2020
pubmed:
14
8
2020
medline:
20
2
2021
Statut:
epublish
Résumé
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is associated with insulin resistance, lipid metabolism, and tumorigenesis. However, the association between the IGF2BP2 polymorphism and oral cancer risk remains unclear. We recruited 1349 male patients with oral cancer and 1198 cancer-free controls. Three single nucleotide polymorphisms IGF2BP2 rs11705701, rs4402960, and rs1470579 were assessed using real-time polymerase chain reaction. The results indicate that the male patients with oral cancer and with the rs11705701 GA+AA, rs4402960 GT+TT, and rs1470579 AC+CC genotypes had increased risk of advanced clinical stage, larger tumor, and progression of lymph node metastasis compared with those with wild-type IGF2BP2. Moreover, according to The Cancer Genome Atlas dataset, high expression of the IGF2BP2 gene is associated with poor survival in patients with head and neck squamous cell carcinoma. In conclusion, our results suggest that IGF2BP2 polymorphisms are associated with less favorable oral cancer clinical characteristics.
Identifiants
pubmed: 32784624
pii: ijms21165662
doi: 10.3390/ijms21165662
pmc: PMC7460642
pii:
doi:
Substances chimiques
IGF2BP2 protein, human
0
RNA, Messenger
0
RNA-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST-108-2320-B-040-012-MY3
Références
Cell Physiol Biochem. 2018;51(4):1945-1956
pubmed: 30513526
Pharmacology. 2014;94(3-4):115-22
pubmed: 25247335
J Mol Endocrinol. 2009 Nov;43(5):187-95
pubmed: 19429674
Mol Cell Biol. 1999 Feb;19(2):1262-70
pubmed: 9891060
Oncotarget. 2017 Nov 7;8(66):110635-110649
pubmed: 29299175
J Cell Mol Med. 2016 Dec;20(12):2231-2240
pubmed: 27605177
Am J Physiol Gastrointest Liver Physiol. 2013 Feb 15;304(4):G328-36
pubmed: 23257922
Cell Oncol (Dordr). 2016 Dec;39(6):545-558
pubmed: 27709558
Rev Diabet Stud. 2012 Summer-Fall;9(2-3):112-22
pubmed: 23403707
Oral Oncol. 2012 Oct;48(10):997-1006
pubmed: 22704062
Eur J Med Res. 2014 Jul 25;19:40
pubmed: 25062844
Int J Environ Res Public Health. 2016 Jun 09;13(6):
pubmed: 27294943
Acta Pharmacol Sin. 2010 Jun;31(6):709-17
pubmed: 20523342
Hum Pathol. 2014 Jul;45(7):1520-8
pubmed: 24814803
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Nat Commun. 2017 Oct 19;8(1):1044
pubmed: 29051499
J Cell Biochem. 2019 Apr;120(4):5510-5518
pubmed: 30335898
Stem Cells Int. 2018 Mar 15;2018:4217259
pubmed: 29736175
Biomed Pharmacother. 2015 Feb;69:297-300
pubmed: 25661373
Cell Death Dis. 2015 Mar 05;6:e1670
pubmed: 25741595
Clin Cancer Res. 2015 Aug 1;21(15):3453-61
pubmed: 25873087
Oncotarget. 2017 Apr 10;8(34):57680-57692
pubmed: 28915704
Elife. 2017 Jul 28;6:
pubmed: 28753127
Chin J Dent Res. 2015;18(1):7-12
pubmed: 25815378
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Cancer Manag Res. 2018 Aug 28;10:2965-2975
pubmed: 30214291
Scand J Immunol. 2015 Aug;82(2):142-3
pubmed: 25916626
Oncotarget. 2016 Aug 2;7(31):49743-49750
pubmed: 27391348
JAMA. 2013 Sep 4;310(9):948-59
pubmed: 24002281
Acta Diabetol. 2009 Sep;46(3):217-26
pubmed: 19082521
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Nov;126(5):415-423
pubmed: 30217459